Brief Title
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Official Title
SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA
Brief Summary
Lorlatinib is a third-generation, oral, reversible, ATP-competitive, macrocyclic TKI of ALK
and ROS1. Lorlatinib was specifically designed to penetrate the CNS and to overcome known
secondary resistance mutations in the ALK tyrosine kinase domain.
This is a Phase 4, open-label, multicenter, non-randomized, prospective, single arm study to
evaluate the safety and tolerability of lorlatinib in adult participants with unresectable
advanced and/or recurrent ALK-positive NSCLC with resistance or intolerance to at least 1
prior ALK inhibitor treatment.
This study is being conducted as a post approval study to fulfill Central Drugs Standard
Control Organization (CDSCO) request relating to additional information on use of Lorlatinib
in Indian patients.
Study Phase
Phase 4
Study Type
Interventional
Primary Outcome
Incidence of Adverse events (AEs)
Secondary Outcome
Percentage of Participants With Objective Responses based on Investigators' assessments
Condition
Advanced Non-Small Cell Lung Cancer
Intervention
Lorlatinib
Study Arms / Comparison Groups
Lorlatinib
Description: The recommended dosage of lorlatinib is 100 mg orally once daily, with or without food, until disease progression, unacceptable toxicity, or participant refusal/lost to follow-up. About 100 participants will be enrolled in this study.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
100
Start Date
August 27, 2020
Completion Date
December 20, 2022
Primary Completion Date
December 20, 2022
Eligibility Criteria
Inclusion Criteria:
1. Evidence of histologically or cytologically confirmed diagnosis of unresectable
advanced and/or recurrent NSCLC that carries an ALK rearrangement, as detected by an
appropriate test.
2. Disease progression or intolerance to 1 previous treatment with ALK TKI. Participants
may have also had prior chemotherapy for their advanced and/or recurrent disease.
3. Participants with asymptomatic CNS metastases (including participants controlled with
stable or decreasing steroid use within the last 2 weeks prior to study enrollment)
will be eligible.
4. Age ≥18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
6. Adequate hematologic and renal function as defined as:
1. Absolute neutrophil count (ANC) ≥1,000/mm3;
2. Platelets ≥50,000/mm3;
3. Hemoglobin ≥8 g/dL;
4. Estimated creatinine clearance ≥30 mL/min as calculated using the method standard
for the institution.
7. Adequate liver function, including:
1. Total serum bilirubin ≤1.5 × upper limit of normal (ULN);
2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
(≤5.0 × ULN in case of liver metastases).
8. Adequate pancreatic function, including:
1. Serum total amylase ≤1.5 × ULN.*
2. Serum lipase <1.5 × ULN. *if total amylase >1.5 × ULN, but pancreatic amylase is
within the ULN, the participant may be enrolled.
9. Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade <1
except for AEs that in the Investigator's judgment do not constitute a safety risk for
the participant.
10. Systemic anticancer therapy completed within a minimum of 5 half-lives of study
enrollment (unless clinically meaningful tumor flare per discretion of the
Investigator, in which discussion with the Sponsor is warranted).
11. Evidence of a personally signed and dated informed consent document indicating that
the participant (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
12. Willingness and ability to comply with the study scheduled visits, treatment plans,
laboratory tests and other procedures.
13. Pregnancy test for females of childbearing potential negative at Screening or female
participants who are not of childbearing potential. Male and female participants of
childbearing potential and at risk for pregnancy must agree to use a highly effective
method of contraception from the time of Screening, throughout the study and for 3
months after the last dose of assigned treatment, 6 months if female participants.
Exclusion Criteria:
1. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study
enrollment. Palliative radiation (<10 fractions) must have been completed at least 48
hours prior to study enrollment. Stereotactic or small field brain irradiation must
have completed at least 2 weeks prior to study enrollment. Whole brain radiation must
have completed at least 4 weeks prior to study enrollment. Prior irradiation to >25%
of the bone marrow.
2. Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port
insertion) are not excluded, but sufficient time should have passed for adequate wound
healing.
3. Known prior or suspected severe hypersensitivity to study drug or any component in its
formulation.
4. Active and clinically significant bacterial, fungal, or viral infection.
5. Clinically significant vascular (both arterial and venous) and non-vascular cardiac
conditions (active or within 3 months prior to enrollment), which may include, but are
not limited to:
1. Arterial disease such as cerebral vascular accident/stroke (including transient
ischemic attack [TIA]), myocardial infarction, unstable angina;
2. Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary
embolism;
3. Non-vascular cardiac disease such as congestive heart failure (New York Heart
Association Classification Class ≥II), second degree or third degree
atrioventricular (AV) block (unless paced) or any AV block with PR interval >220
msec; or ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial
fibrillation of any grade, bradycardia defined as <50 beats per minute (bpm)
(unless participant is otherwise healthy such as long distance runners, etc.),
machine read ECG with QT interval corrected for heart rate (QTc) >470 msec, or
congenital long QT syndrome.
6. History or known presence of interstitial fibrosis, interstitial lung disease (ILD),
pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative
bronchiolitis, and pulmonary fibrosis.
7. Other severe acute or chronic medical or psychiatric condition, including recent
(within the past year) or active suicidal ideation or behavior, or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the Investigator, would make the participant
inappropriate for enrollment in this study.
8. Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in
situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ [DCIS] of the
breast or localized and presumed cured prostate cancer) within the last 3 years prior
to enrollment.
9. Concurrent use of any of the following food or drugs (consult the Sponsor if in doubt
whether a food or a drug falls into any of the categories described below) within 12
days prior to the first dose of lorlatinib:
1. Known strong cytochrome (CYP)3A inducers (eg, carbamazepine, enzalutamide,
mitotane, rifampin, St. John's Wort).
2. Known strong CYP3A inhibitors (eg, grapefruit juice or grapefruit/grapefruit
related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat,
clarithromycin, conivaptan, diltiazem, idelalisib, indinavir, itraconazole,
ketoconazole, lopinavir, nelfinavir, paritaprevir, posaconazole, ritonavir alone
and with elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or
dasabuvir or saquinavir or tipranavir, telaprevir and voriconazole). The topical
use of these medications (if applicable), such as 2% ketoconazole cream, is
allowed.
3. Known CYP3A substrates with narrow therapeutic index, such as pimozide,
quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including
transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine).
4. Known permeability glycoprotein (P-gp) substrates with a narrow therapeutic index
(eg, digoxin).
10. Participants who are investigational site staff members directly involved in the
conduct of the study and their family members, site staff members otherwise supervised
by the Investigator, or participants who are Pfizer employees directly involved in the
conduct of the study.
11. Participation in other studies involving investigational drug(s) (Phases 1-4) during
study participation.
12. Breastfeeding female participants.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, 1-800-718-1021, [email protected]
Location Countries
India
Location Countries
India
Administrative Informations
NCT ID
NCT04541706
Organization ID
B7461030
Responsible Party
Sponsor
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
February 2021